2 completed, 2 withdrawn, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Withdrawn 2, Terminated 1 |
Follow Cemdisiran: new trials by email Literature Review of Cemdisiran trials Research Report on Cemdisiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Regeneron Pharmaceuticals | 24 | 2021-07-29 | 2025-04-08 |
| Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Regeneron Pharmaceuticals | 6 | 2021-07-08 | 2025-08-29 |
| Eculizumab to Cemdisiran Switch in aHUS cemdisiran, Placebos - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Mario Negri Institute for Pharmacological Research | 2021-01-01 | 2021-03-10 | |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Placebo, Cemdisiran - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Terminated | Alnylam Pharmaceuticals | 31 | 2019-09-30 | 2024-08-09 |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Cemdisiran - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Alnylam Pharmaceuticals | 2017-09-19 | 2018-10-01 |
Atypical Hemolytic Uremic Syndrome (2) · Hemoglobinuria, Paroxysmal (2) · Glomerulonephritis, IGA (1) · Hemolysis (1) · Renal Insufficiency (1) · Thrombocytopenia (1) · Thrombotic Microangiopathies (1)
Alnylam Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · Mario Negri Institute for Pharmacological Research (1)
United Kingdom (3) · Canada (2) · Malaysia (2) · Sweden (2) · Taiwan (2) · Bosnia and Herzegovina (1) · Estonia (1) · France (1) · Georgia (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Latvia (1) · Lithuania (1) · Moldova (1)
2018 (2)